Evidence map›Paper›PMID 40498178›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Nontargeted Metabolomics Using the Sciex ZenoTOF 7600.

Anna Artati, Pauline Couacault, Michael Witting

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. RPLC- and HILIC-based non-targeted metabolomics workflow for blood microsamples.Metabolomics : Official journal of the Metabolomic Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anna ArtatiMetabolomics and Proteomics Core, Helmholtz Zentrum München GmbH, Neuherberg, Germany.
Pauline CouacaultMetabolomics and Proteomics Core, Helmholtz Zentrum München GmbH, Neuherberg, Germany.
Michael WittingMetabolomics and Proteomics Core, Helmholtz Zentrum München GmbH, Neuherberg, Germany. michael.witting@helmholtz-munich.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nontargeted metabolomics aims to capture as many metabolites as possible present in a biological system under a certain condition. Despite several analytical techniques commonly applied for nontargeted metabolomics, liquid chromatography coupled to high-resolution tandem mass spectrometry (LC-HRMS/MS) is one of the most employed techniques. To cover broad metabolic classes, different chromatographic separation techniques are implemented, i.e., reversed-phase (RP) and hydrophilic interaction liquid chromatography (HILIC) techniques. Each method offers a complementary polarity range. While RP covers semi- to nonpolar metabolites, such as fatty acids, acylcarnitines, steroids, bile acids, etc., HILIC allows the analysis of polar metabolites, such as amino acids, amines, and organic acids.Nontargeted metabolomics platforms at Helmholtz Munich have been validated for various biological matrices, including biological liquids (plasma, serum, urine), tissues (liver, heart), and cell samples of human and rodent. Analysis is based on the Sciex ZenoTOF 7600 and three chromatographic separation methods, which can be used individually or in combination.

Indexed as

MetabolomeMetabolomicsAnimalsChromatography, LiquidChromatography, Reverse-PhaseHumansHydrophobic and Hydrophilic InteractionsTandem Mass SpectrometryHydrophilic interaction liquid chromatography (HILIC)LC-HRMS/MSMetabolomicsNon-targetedReversed phase (RP)

Identifiers

PMID40498178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.